Xenon Pharmaceuticals XENE Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $7.5M— | $0— | $0-100% | $9.43M-48.8% | ||
| $300.94M+43.0% | $210.39M+25.6% | $167.51M+58.4% | $105.77M+40.2% | ||
| $79.63M+15.6% | $68.9M+48.0% | $46.54M+41.9% | $32.81M+49.4% | ||
| $380.57M+36.3% | $279.3M+30.5% | $214.05M+54.5% | $138.58M+42.2% | ||
| $380.57M+36.3% | $279.3M+30.5% | $214.05M+54.5% | $138.58M+42.2% | ||
| -$373.07M-33.6% | -$279.3M-30.5% | -$214.05M-65.7% | -$129.14M-63.5% | ||
| -4,974.3%— | —— | —— | -1,368.9%-940pp | ||
| $26.83M-36.0% | $41.94M+51.9% | $27.62M+217% | $8.71M+1,770% | ||
| $28.18M-31.1% | $40.88M+30.3% | $31.37M+707% | $3.89M— | ||
| -$344.89M-44.7% | -$238.42M-30.5% | -$182.69M-45.9% | -$125.26M-58.8% | ||
| $1.02M+125% | -$4.09M-1,300% | -$292K-347% | $118K— | ||
| -$345.91M-47.6% | -$234.33M-28.5% | -$182.39M-45.5% | -$125.37M-58.9% | ||
| -4,612.1%— | —— | —— | -1,328.9%-901pp | ||
| -$4.36-44.4% | -$3.02-11.0% | -$2.72-33.3% | -$2.04-15.3% | ||
| -$4.36-44.4% | -$3.02-11.0% | -$2.72-33.3% | -$2.04-15.3% | ||
| 316.1M+1.6% | 311.1M+17.6% | 264.5M+11.6% | 237.1M+43.8% | ||
| 316.1M+1.6% | 311.1M+17.6% | 264.5M+11.6% | 237.1M— | ||
| -$343.96M-45.8% | -$235.87M-31.4% | -$179.47M-40.9% | -$127.38M— | ||
| —— | -$1.06M— | —— | —— | ||
| $2.09M+236% | -$1.54M-153% | $2.92M+245% | -$2.01M— | ||
| -$373.07M-33.6% | -$279.3M-30.5% | -$214.05M-65.7% | -$129.14M-63.5% | ||
| -$370.53M-33.9% | -$276.74M— | —— | -$127.74M-63.6% | ||
| -$370.53M-33.9% | -$276.74M— | —— | -$127.74M-63.6% | ||
| -4,940.4%— | —— | —— | -1,354%-930pp | ||
| -$373.07M-33.6% | -$279.3M-30.5% | -$214.05M-65.7% | -$129.14M-63.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Xenon Pharmaceuticals's income statement data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.